Jefferies Maintains Neuren Pharmaceuticals' Daybue Royalty Timeline

MT Newswires Live

06/30

Neuren Pharmaceuticals (ASX:NEU) is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027 following a positive opinion from a committee of the European health regulator, Jefferies said in a note on Monday, reaffirming its timeline projection.

Neuren's partner, Acadia Pharmaceuticals, received the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older.

Final approval now depends on the European Commission's decision, which is expected in the coming months.

Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2647300779"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2647300779\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2647300779?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 07:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647300779","market":"fut","top_or_hot":-1,"title":"Jefferies Maintains Neuren Pharmaceuticals' Daybue Royalty Timeline","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> (ASX:NEU) is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027 following a positive opinion from a committee of the European health regulator, Jefferies said in a note on Monday, reaffirming its timeline projection.</p><p>Neuren's partner, Acadia Pharmaceuticals, received the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older.</p><p>Final approval now depends on the European Commission's decision, which is expected in the coming months.</p><p>Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jefferies Maintains Neuren Pharmaceuticals' Daybue Royalty Timeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJefferies Maintains Neuren Pharmaceuticals' Daybue Royalty Timeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-30 07:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NEU.AU\">Neuren Pharmaceuticals</a> (ASX:NEU) is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027 following a positive opinion from a committee of the European health regulator, Jefferies said in a note on Monday, reaffirming its timeline projection.</p><p>Neuren's partner, Acadia Pharmaceuticals, received the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older.</p><p>Final approval now depends on the European Commission's decision, which is expected in the coming months.</p><p>Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2647300779","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647300779","pubTimestamp":1782774529,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neuren Pharmaceuticals  is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027 following a positive opinion from a committee of the European health regulator, Jefferies said in a note on Monday, reaffirming its timeline projection.Neuren's partner, Acadia Pharmaceuticals, received the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older.Final approval now depends on the European Commission's decision, which is expected in the coming months.Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK7096":"制药","EPV":"ProShares UltraShort MSCI Europe"},"translate_title":"杰富瑞维持Neuren Pharmaceuticals的Daybue特许权使用费时间表","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":1,"EPV":0.78},"content_text":"Neuren Pharmaceuticals (ASX:NEU) is expected to receive royalties from European Daybue sales in the first quarter of fiscal year 2027 following a positive opinion from a committee of the European health regulator, Jefferies said in a note on Monday, reaffirming its timeline projection.Neuren's partner, Acadia Pharmaceuticals, received the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding Daybue, which is used to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older.Final approval now depends on the European Commission's decision, which is expected in the coming months.Jefferies maintained its buy rating and price target of AU$28 on Neuren Pharmaceuticals.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}